<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800423</url>
  </required_header>
  <id_info>
    <org_study_id>5189</org_study_id>
    <nct_id>NCT00800423</nct_id>
  </id_info>
  <brief_title>Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema</brief_title>
  <official_title>Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients undergoing cataract surgery suffer from corneal edema after the surgery.

      Brimonidine drops are a well known and safe Anti-glaucoma medication. the investigators have
      made several clinical observations that patients receiving Brimonidine drops had a faster
      resolution of their corneal edema even if they had normal intra-ocular pressure.

      The investigators believe that administering topical Brimonidine to patients with significant
      post operative corneal edema will hasten the resolution of their corneal edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most patients undergoing cataract surgery suffer from corneal edema after the surgery which
      temporarily reduces their visual acuity until corneal edema resolves over several weeks
      Brimonidine drops are a well known and safe Anti-glaucoma medication, used to lower intra
      ocular pressure.

      there have been several clinical observations that patients receiving Brimonidine drops had a
      faster resolution of their corneal edema even in the presence of normal intra-ocular
      pressure.

      The investigators postulated that administering topical Brimonidine to patients with
      significant post operative corneal edema will hasten their recovery and visual improvement.

      In order to prove that Brimonidine drops contribute to faster resolution of cornel edema and
      visual improvement, the study will randomly compare 50 post cataract surgery patients (group
      A)who will be administered Brimonidine to 2 control groups (50 people in each group):

      group B will be given topical timolol drops 0.5% (another well recognized anti glaucoma
      medication which reduces intra-ocular pressure by different mechanism than Brimonidine.

      Group C will not be given any test drug. All 3 groups will receive the regular post operative
      medications which include corticosteroids and antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central corneal thickness in micrometer</measure>
    <time_frame>day 0 (day of enrollment ), day 7, day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>grading of corneal edema (1-3)</measure>
    <time_frame>day 0 (day of enrollment), day 7, day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Corneal Edema</condition>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>brimonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.
they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 tmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients receiving timolol maleate 0.5% drops in the operated eye
1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate 0.2%</intervention_name>
    <description>Brimonidine Tartrate 0.2% drops
1 drop twice a day for 1 month in the operated eye</description>
    <arm_group_label>brimonidine</arm_group_label>
    <other_name>ALPHAGAN P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol maleate 0.5%</intervention_name>
    <description>timolol maleate 0.5% drops
1 drop twice a day for 1 month in the operated eye</description>
    <arm_group_label>2 tmolol</arm_group_label>
    <other_name>TILOPTIC</other_name>
    <other_name>V-OPTIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 day after uneventful cataract surgery

          -  corneal edema (grade 2 to 3)

        Exclusion Criteria:

          -  glaucoma

          -  higher than normal intraocular pressure (&gt;23 mm Hg)

          -  known sensitivity or contra indication to brimonidine

          -  known sensitivity or contra indication to timolol

          -  pre operative corneal or anterior segment disease

          -  intraoperative complications

          -  major ocular pathology other than corneal that reduced vision (retinal degeneration,
             optic neuropathy etc.)

          -  pregnant women

          -  children
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin medical center, Clalit health services , Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anat Robinson, MD</last_name>
    <phone>9729377176</phone>
    <email>robina@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omer Y Bialer, MD</last_name>
    <phone>9729377171</phone>
    <email>omerb@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin medical center ophthalmology deparment</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weinberger Dov, MD</last_name>
      <phone>9729376101</phone>
      <email>dwin@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Omer bialer, MD</last_name>
      <phone>9729377171</phone>
      <email>omerb@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>omer y bialer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anat Robinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>December 1, 2008</last_update_submitted>
  <last_update_submitted_qc>December 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Robinson Anat</name_title>
    <organization>Rabin Medical Center</organization>
  </responsible_party>
  <keyword>corneal edema</keyword>
  <keyword>postoperative corneal edema</keyword>
  <keyword>central corneal thickness</keyword>
  <keyword>visual acuity</keyword>
  <keyword>postoperative</keyword>
  <keyword>brimonidine</keyword>
  <keyword>timolol</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

